Rituximab use in young adults diagnosed with juvenile idiopathic arthritis unresponsive to conventional treatment: Report of 6 cases

Revista Brasileira de Reumatologia

Volumn 55, Issue 6, 2015, Pages 536-541

  Sakamoto, Ana Paula ^a   Pinheiro, Marcelo M ^a   Barbosa, Cássia Maria Passarelli Lupoli ^b   Fraga, Melissa Mariti ^a   Len, Claudio Arnaldo ^a   Terreri, Maria Teresa ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Hospital Infantil Darcy Vargas   (Brazil)

Author keywords

Children; Juvenile idiopathic arthritis; Refractoriness; Rituximab

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIHISTAMINIC AGENT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; GLUCOCORTICOID; INDOMETACIN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; NAPROXEN; PREDNISONE; RHEUMATOID FACTOR; RITUXIMAB; SALAZOSULFAPYRIDINE; THALIDOMIDE; TOCILIZUMAB; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR;

ADULT; ANAPHYLAXIS; ANEMIA; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CROHN DISEASE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTHESITIS; FEMALE; HIP ARTHROPLASTY; HUMAN; INFUSION RELATED REACTION; INTESTINE FISTULA; JUVENILE RHEUMATOID ARTHRITIS; MACROPHAGE ACTIVATION SYNDROME; MALE; MULTIPLE CYCLE TREATMENT; SERUM SICKNESS; UNSPECIFIED SIDE EFFECT; YOUNG ADULT; ANTAGONISTS AND INHIBITORS; CASE REPORT; TREATMENT OUTCOME; DAS28; HEALTH ASSESSMENT QUESTIONNAIRE; ONSET AGE; TREATMENT RESPONSE;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; FEMALE; HUMANS; MALE; RITUXIMAB; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84952327998     PISSN: 04825004     EISSN: 18094570     Source Type: Journal    
DOI: 10.1016/j.rbre.2015.05.002     Document Type: Article

References (23)

1. Cassidy JT, Petty RE. Textbook of pediatric rheumatology.6th ed. Philadelphia: Elsevier; 2011.
2. Alexeeva EI, Valieva SI, Bzarova TM, Semikina EL, Isaeva KB, Lisitsyn AO, et al. Efficacy and safety of repeated courses ofrituximab treatment in patients with severe refractoryjuvenile idiopathic arthritis. Clin Rheumatol. 2011;30:1163-72.
3. Jansson AF, Sengler C, Kuemmerle-Deschner J, Gruhn B, Kranz AB, Lehmann H, et al. B cell depletion for autoimmunediseases in paediatric patients. Clin Rheumatol.2005;30:87-97.
4. Marks SD, Patey S, Brogan PA, Hasson N, Pilkington C, Woo P, et al. B Lymphocyte depletion therapy in children withrefractory systemic lupus erythematosus. Arthritis Rheum.2006;52:3168-74.
5. El-Hallak M, Binstadt BA, Leichtner AM, Bennet CM, Neufeld EJ, Fuhlbrigge RC, et al. Clinical effects and safety ofrituximab for treatment of refractory pediatric autoimmunediseases. J Pediatr. 2007;150:376-82.
6. Kuek A, Hazleman BL, Gaston JH, Östör AJK. Successfultreatment of refractory polyarticular juvenile idiopathicarthritis with rituximab. Rheumatology. 2006;45:1448-9.
7. Feito JG, Pereda CA. Rituximab therapy produced rapid andsustained clinical improvement in a patient with systemiconset juvenile idiopathic arthritis refractory to TNF alphaantagonists. J Clin Rheumatol. 2009;15:363-5.
8. Weiner GJ. Rituximab: mechanism of action. Semin Hematol.2010;47:115-23.
9. Leandro MJ, Edwards JCW, Cambridge G. Clinical outcome in22 patients with rheumatoid arthritis treated with Blymphocyte depletion. Ann Rheum Dis. 2002;61:883-8.
10. Keystone E, Burmester GR, Furie R, Loveless JE, Emery P, Kremer J, et al. Improvement in patient-reported outcomes ina rituximab trial in patients with severe rheumatoid arthritisrefractory to anti-tumor necrosis factor therapy. Arthritis Rheum. 2008;59:785-93.
11. Keystone E, Emery P, Peterfy CG, Tak PP, Cohen S, Genovese MC, et al. Rituximab inhibits structural joint damage inpatients with rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitor therapies. Ann Rheum Dis. 2009;68:216-21.
12. Nasonov EL. New trends in treatment of rheumatoid arthritis:perspectives of use of monoclononal anti-B-lymphocyteantibodies (rituximab). Russ Med J. 2006;25:1778-82.
13. Petty RE, Southwood TR, Manners E, Baum J, Glass DN, He X, et al. International League of Association for Rheumatologyclassification of juvenile idiopathic arthritis: second revision.J Rheumatol. 2004;31:390-2.
14. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores thatinclude twenty-eight-joint counts. Development andvalidation in a prospective longitudinal study of patients withrheumatoid arthritis. Arthritis Rheum. 1995;38:44-8.
15. Ferraz MB, Oliveira LM, Araujo PM, Atra E, Tugwell P.Cross-cultural reliability of the physical ability dimension ofthe health assessment questionnaire. J Rheumatol.1990;17:813-7.
16. Machado CSM, Ruperto N, Silva CHM, Ferriani VP, Roscoe I, Campos LM, et al. The Brazilian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol. 2001;19Suppl. 23:S25-9.
17. van Gestel AM, Prevoo ML, van Hof MA, van Rijswijk MH, vande Putte LBA, van Riel PLCM. Development and validation ofthe European League Against Rheumatism response criteriafor rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatismcriteria. Arthritis Rheum. 1996;39:34-40.
18. Kasher-Meron M, Uziel Y, Amital H. Successful treatmentwith B-cell depleting therapy for refractory systemic onsetjuvenile idiopathic arthritis: a case report. Rheumatology.2009;48:445-6.
19. Narváez J, Diaz-Torné C, Juanola X, Geli C, Llobet JM, Nolla JM, et al. Rituximab therapy for refractory systemic-onsetjuvenile idiopathic arthritis. Ann Rheum Dis. 2009;68:607-8.
20. Morbach H, Wiegering V, Richl P, Schwarz T, Suffa N, Eichhorn EM, et al. Activated memory B cells may function asantigen-presenting cells in the joints of children with juvenileidiopathic arthritis. Arthritis Rheum. 2011;63:3458-66.
21. Morbach H, Girschick HJ. B-cell targeted therapy for childrenand adolescents with rheumatic diseases. Z Rheumatol.2013;72:347-53.
22. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacyand safety of rituximab in patients with active rheumatoidarthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54:1390-400.
23. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC. Rituximab for rheumatoid arthritis refractoryto anti-tumor necrosis factor therapy: results of amulticenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety attwenty-four weeks. Arthritis Rheum. 2006;54:2793-806.